New Immunotherapy Study Findings Recently Were Reported by Researchers at University of Washington (CD19CAR T Cells From Humble Beginnings to Cancer Immunotherapy's Poster Child)
By a News Reporter-Staff News Editor at Cancer Vaccine Week -- A new study on Biotechnology is now available. According to news reporting originating from Seattle, Washington, by NewsRx correspondents, research stated, "The conceptual foundation and technical evolution of T-cell genetic engineering for the purpose of retargeting antigen specificity as a clinical immunotherapy modality in oncology have been decades in the making, with many laboratories providing important contributions to overall progress. The development of the component parts of this technology has required the amalgamation of divergent scientific disciplines including cellular immunology, lymphocyte signaling biology, molecular biology, vector virology, and practical improvements in T-cell culture systems."
Our news editors obtained a quote from the research from the University of Washington, "Together with advances in the understanding of clinical variables that facilitate persistent engraftment and expansion of adoptively transferred T cells, the field of CD19CAR research evolved as a logical venue for revealing proof-of-principle clinical antitumor activity. Indeed, the modality has definitively crossed the threshold from a preclinical model system to a therapeutic approach with demonstrable potent antileukemic efficacy in patients harboring advanced and refractory leukemias."
According to the news editors, the research concluded: "The dramatic responses seen in CD19CAR T-cell clinical trials from multiple institutions does not signal an end to the evolution of CD19CAR T cells, as along with early clinical successes, new challenges have emerged that require further refinement of this nascent therapeutic platform."
For more information on this research see: CD19CAR T Cells From Humble Beginnings to Cancer Immunotherapy's Poster Child. Cancer Journal, 2014;20(2):107-111. Cancer Journal can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA (see also Biotechnology).
The news editors report that additional information may be obtained by contacting R.A. Gardner, University of Washington, Sch Med, Dept. of Bioengn, Seattle, WA, United States.
Keywords for this news article include: Biotechnology, Cancer, Seattle, Genetics, Oncology, Washington, United States, Immunotherapy, Immunomodulation, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC